Research Paper Volume 12, Issue 15 pp 15656—15669

CTLA-4 immunotherapy exposes differences in immune response along with different tumor progression in colorectal cancer


Figure 1.

Different tumor sizes depending on the start treatment (100 to 800 mm3) of the subcutaneously inoculated CT26 show the different anti-tumor effects. The cell numbers of inoculation is 3 × 105 into 100 ul for each mouse. Tumor volume trace after administering anti-CTLA-4 Ab to female BALB/c mice inoculated with the CT26 syngeneic model. (A) Volume of tumors from mice inoculated with CT26 subcutaneously. Mean tumor volumes (mm3) ± SE (n = 5 mice per group) are shown. Data are statistically significant for anti-CTLA-4 antibody 10 mg/kg intraperitoneal injection, weekly; ***, P < 0.001, on day 17. (B) Photos of the tumors isolated from mice inoculated with CT26 cells in the study.